Flarex

Edema, Inflammation, Uveitis, Anterior + 5 more
Treatment
2 FDA approvals
20 Active Studies for Flarex

What is Flarex

FluorometholoneThe Generic name of this drug
Treatment SummaryPrednisolone is a steroid eye drop that is used to reduce inflammation and allergies in the eyes. It can also be used to treat skin conditions such as eczema and psoriasis.
FMLis the brand name
image of different drug pills on a surface
Flarex Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
FML
Fluorometholone
1972
11

Approved as Treatment by the FDA

Fluorometholone, also called FML, is approved by the FDA for 2 uses such as Ocular Inflammation and Conjunctivitis .
Ocular Inflammation
Conjunctivitis

Effectiveness

How Flarex Affects PatientsCorticosteroids, such as fluorometholone, help reduce inflammation caused by a variety of agents, but can also slow down the healing process. They work by decreasing swelling, stopping the formation of blood clots, preventing white blood cells from gathering at the site of inflammation, blocking the growth of new blood vessels, stopping the growth of cells that produce collagen and scar tissue, and reducing the formation of scars.
How Flarex works in the bodyOcular corticosteroids are believed to reduce inflammation by blocking the formation of certain molecules that cause inflammation. This is done by creating proteins called lipocortins that stop the release of the building block of these molecules, called arachidonic acid. Corticosteroid drugs then bind to a receptor inside a cell nucleus, causing the expression of certain genes that control inflammation.

When to interrupt dosage

The prescribed dosage of Flarex is contingent upon the diagnosed affliction, including Anterior chamber inflammation, eye surgery and Ocular Inflammation. The magnitude of dosage hinges upon the methodology of delivery (e.g. Ointment - Ophthalmic or Suspension - Ophthalmic) featured in the table below.
Condition
Dosage
Administration
Edema
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
Inflammation
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
Uveitis, Anterior
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
ocular bacterial infections
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
eye surgery
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
Conjunctivitis
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
Allergic Conjunctivitis (AC)
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic
Vascular injection
0.001 mg/mg, , 1.0 mg/mL, 2.5 mg/mL, 0.1 %, 0.25 %, 0.001 mL/mL
, Ophthalmic, Ointment, Ointment - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Suspension, Suspension - Ophthalmic

Warnings

Flarex has five contraindications and ought not be combined with any of the circumstances noted in the following table.Flarex Contraindications
Condition
Risk Level
Notes
Eye
Do Not Combine
conjunctiva
Do Not Combine
conjunctiva
Do Not Combine
Herpes Zoster Ophthalmicus
Do Not Combine
Eye Infections, Fungal
Do Not Combine
There are 20 known major drug interactions with Flarex.
Common Flarex Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Fluorometholone is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Fluorometholone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Acteoside.
Flarex Toxicity & Overdose RiskSide effects of corticosteroids can include inflammation of the front of the eye, inflammation of the cornea, redness of the eyes, and drooping of the eyelid. In high doses, corticosteroids can be fatal to rats, with a lethal dose of 234mg/kg.
image of a doctor in a lab doing drug, clinical research

Flarex Novel Uses: Which Conditions Have a Clinical Trial Featuring Flarex?

189 active clinical trials are presently exploring the potential benefits of Flarex in mitigating Inflammation, Swelling and Ocular Inflammation.
Condition
Clinical Trials
Trial Phases
Edema
0 Actively Recruiting
Uveitis, Anterior
0 Actively Recruiting
eye surgery
0 Actively Recruiting
Inflammation
58 Actively Recruiting
Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4
Allergic Conjunctivitis (AC)
1 Actively Recruiting
Phase 2
Conjunctivitis
0 Actively Recruiting
ocular bacterial infections
0 Actively Recruiting
Vascular injection
0 Actively Recruiting

Flarex Reviews: What are patients saying about Flarex?

5Patient Review
2/12/2010
Flarex for Inflammation of the Eye Following Surgery
This drug is amazing, my eyes felt better within a day!
5Patient Review
10/18/2009
Flarex for Allergic Conjunctivitis
3.3Patient Review
6/3/2014
Flarex for Inflammation of the Eye
I was using this as directed by my doctor, but then Alcon discontinued the product. I'm very disappointed.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about flarex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long should you use Flarex?

"If your symptoms do not improve after 2 days of treatment, call your doctor. If you use this medicine for longer than 10 days, you may needfrequent vision tests to check the pressure inside your eyes."

Answered by AI

How often can I use Flarex?

"For eye conditions caused by swelling, adults should use one drop in the affected eye two to four times a day. For the first 24 to 48 hours, the medicine can be used every 4 hours, as directed by a doctor."

Answered by AI

What are Flarex drops used for?

"This medication is meant to treat conditions that cause inflammation in the eye, such as the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye."

Answered by AI

How long does it take Flarex to work?

"The goal for using generic fluorometholone suspension, FML, or FML Forte is that the inflammation and pain in your eye should get better within 2 days. The goal for using Flarex is that your symptoms should improve within 2 weeks."

Answered by AI

Clinical Trials for Flarex

Image of UConn Health in Farmington, United States.

Cognitive Remediation for Memory and Thinking Difficulties

18+
All Sexes
Farmington, CT
The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are: * Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction? * Will treatment effects be maintained over time, leading to better long term cognitive outcomes? * Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement? * Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction. Participation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including: * Initial intake visit: Eligibility confirmation (\~2-3 hours) * Computer activities: About 5 hours per week for \~6 weeks (total \~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase * Weekly remote check-in meetings: \~30 minutes each during treatment * Blood draws: Two sessions (before and after treatment), \~20-30 minutes each * Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)
Waitlist Available
Has No Placebo
UConn HealthCutter Lindbergh, Ph.D.
Have you considered Flarex clinical trials? We made a collection of clinical trials featuring Flarex, we think they might fit your search criteria.Go to Trials
Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Phase 2
Recruiting
Abcentra Investigational Site (+6 Sites)Abcentra
Image of School of Public Health in Bloomington, United States.

High Salt Intake for High Blood Pressure

60 - 85
All Sexes
Bloomington, IN
Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury/impaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.
Recruiting
Has No Placebo
School of Public Health
Image of Tesla MedBed at Tampa-FL in Tampa, United States.

Biophoton Therapy for Stem Cell Proliferation

18 - 70
All Sexes
Tampa, FL
Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.
Recruiting
Online Trial
Tesla MedBed at Tampa-FL (+1 Sites)James Z Liu, MD, PhD
Have you considered Flarex clinical trials? We made a collection of clinical trials featuring Flarex, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

Moisturizers for Aging

65+
All Sexes
San Francisco, CA
This is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin. The overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation. The primary objective is to determine the feasibility for a larger trial, and the secondary objectives are to determine the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers. Participants will be asked to apply one of two topical moisturizers that are widely available over the counter in the US (Vaseline® 100% pure petroleum jelly or CeraVe® moisturizing cream) once daily for 4 weeks to the front of the torso, buttocks, arms, and legs. Subjects will act as their own control (i.e. they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period). Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment groups: i. no intervention then CeraVe; ii. CeraVe then no intervention; iii. no intervention then Vaseline; iv. Vaseline then no intervention. At each visit (baseline, week 4, and week 8), participants will undergo skin barrier testing, skin microbiome sampling, and phlebotomy to measure serum inflammatory markers.
Phase 4
Recruiting
UCSFKatrina Abuabara, MD
Have you considered Flarex clinical trials? We made a collection of clinical trials featuring Flarex, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security